Exploratory analysis of the phase II VALENTINO trial (154 patients with RAS wild-type mCRC on panitumumab/FOLFOX): baseline ctDNA (72.7%) was linked to higher death risk (HR 2.24), and persistence at 8 weeks to higher progression (2.70) and death risk (HR 3.37).
Secondary analysisn = 154
Manca et al. ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial